USAID helping to move health forward in Burma

Ariel Pablos-Mendez, USAID assistant administrator for global health, writes in the agency's IMPACTblog about his recent trip to Burma and the challenges the country faces as it transitions to an open society. "Hope springs anew for a transformative era of peace, prosperity and development for a country that's just emerging from isolation from the international community," he says, adding, "[W]hile maternal and child health, HIV/AIDS, [tuberculosis (TB)] and malaria are obvious targets for investment, there was a strong emphasis on the importance of strengthening health systems and stemming the growing problem of chronic diseases and injuries." Pablos-Mendez continues, "New commitments in health" from the country's leadership, the U.S., and other partners "hold promise for the Burmese people" (11/14).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024